Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06021483 | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | recruiting | — | 300 | Boryung Pharmaceutical Co., LtdINDUSTRY |
| 1 |
| Sep 16, 2025 |
| clinicaltrials |
| NCT07161882 | ALG-LungCancerRegistry (SAFRO2202)(SAFRO2202) | recruiting | — | 3,750 | Société Algérienne de Formation et de Recherche en OncologieOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06732193 | Fissios© and Postoperative Complications (FPoC Trial)(FPoC) | recruiting | N/A | 560 | Carlos Alfredo Fraile Olivero, MD, PhD.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05094843 | The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery | recruiting | — | 100 | Tampere University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05277844 | Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC(TARGET-01) | recruiting | Phase 2 | 106 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05557487 | Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration(TRIO) | recruiting | — | 6,618 | Gee-Chen ChangOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06202222 | Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung Resection(IRPOL) | recruiting | N/A | 184 | University Hospital, RouenOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166003 | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer(NeoIP-Lung) | recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06512207 | A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer | recruiting | N/A | 80 | Jinzhou Medical UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06262321 | Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax(DRO2301) | recruiting | Phase 2 | 48 | University of RochesterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06548711 | Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer | recruiting | N/A | 84 | Kong FanmingOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06868485 | A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Wayshine Biopharm, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT07150663 | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 134 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05903430 | A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)(MIDSECTION) | recruiting | — | 60 | The Christie NHS Foundation TrustOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06127303 | Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC | recruiting | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | recruiting | Phase 4 | 302 | Pharmacosmos A/SINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04300062 | Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer(REBIMMUNE) | recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06942143 | An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | recruiting | Phase 1 | 15 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06076005 | Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor(LUNG-CANCER) | recruiting | — | 1,000 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06276530 | Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling(VaPosVent) | recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06483698 | Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery(EarlyLC-RW) | recruiting | — | 20,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06784791 | Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)(NEOpredict-EGF) | recruiting | Phase 2 | 20 | University Hospital, EssenOTHER | 3 | Aug 29, 2025 | clinicaltrials |
| NCT06529081 | Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer | recruiting | N/A | 165 | Copernicus Memorial HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04527419 | SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009) | recruiting | N/A | 545 | Fudan UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07056556 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06258642 | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | recruiting | N/A | 39 | Fudan UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131163 | Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection(NoSurgery) | recruiting | — | 60 | Sheba Medical CenterOTHER_GOV | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131670 | Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes(ePRO-LC-CRT) | recruiting | — | 100 | Qian ChuOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07130032 | Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade(reICB) | recruiting | Phase 2 | 90 | EuroCityClinic LLCNETWORK | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT06907615 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 243 | Shanghai Henlius BiotechINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT05049837 | PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification | recruiting | — | 7,200 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06634979 | Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm | recruiting | N/A | 684 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07018960 | "Multicenter Registry for Chest Wall Reconstruction Using Custom Dynamic Prostheses (PRODIPET)"(PRODIPET) | recruiting | N/A | 60 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06861543 | The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)(TMT101-01) | recruiting | Phase 1 | 18 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07004868 | Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study(LCab) | recruiting | — | 150 | University Hospital, ToursOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06896422 | Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC | recruiting | Phase 1 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07109401 | Perioperative Immunotherapy for Resectable Limited-Stage SCLC | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2025source: clinicaltrials